HIV-1 protease continues to be a major target for therapy against AIDS. Although there are
ten FDA approved drugs available, long term use of these drugs elicit drug resistant …

ABSTRACT A detailed computational study was performed to investigate the conformational
changes of flap region and the mechanism underlying the binding of the inhibitor TMC-126 …

Inhibitors of HIV-1 protease (HIV-1-pr) generally only bind to the active site of the protease.
However, for some mutants such as V32I and M46L the TMC114 can bind not only to the …

The single mutations D30N and I50V are considered as the key residue mutations of the HIV-
1 protease drug resistance to inhibitors in clinical use. In this work, molecular dynamics (MD) …

TMC114 (darunavir) is a promising clinical inhibitor of HIV-1 protease (PR) for treatment of
drug resistant HIV/AIDS. We report the ultra-high 0.84 Å resolution crystal structure of the …

Antiretroviral drug resistance is a therapeutic obstacle for people with HIV. HIV protease
inhibitors darunavir and lopinavir are recommended for resistant infections. We …

The binding properties of the protein–inhibitor complex of human immunodeficiency virus
type 1 (HIV-1) protease with the inhibitor TMC-126 are investigated by combining …

The PR20 HIV-1 protease, a variant with 20 mutations, exhibits high levels of multi-drug
resistance; however, to date, there has been no report detailing the impact of these 20 …

Acquired immune deficiency syndrome (AIDS) is caused by the human immunodeficiency
virus (HIV), type 1 and 2. Further, the diversity in HIV-1 has given rise to many serotypes and …

HIV‐1 protease has been an important drug target for the antiretroviral treatment of HIV
infection. The efficacy of protease drugs is impaired by the rapid emergence of resistant …